Recurrent Melanoma Recruiting Phase 1 Trials for Selinexor (DB11942)

Also known as: Melanoma Recurrent

IndicationStatusPhase
DBCOND0028662 (Recurrent Melanoma)Recruiting1
clinicaltrials.gov IdentifierTitlePurposeDrugs
NCT02120222Evaluating SINE KPT-330 in Treating Patients With Melanoma That Cannot Be Removed By SurgeryTreatment